Patients with Alzheimer’s disease experienced rapid and significant improvements in agitation with a combination of CBD and ...
Biomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026 ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA ® (enlicitide) tablets 20 mg as an adjunct ...
Fractyl Health, Inc. (Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to ...
Dementia prevention is becoming a testable public health strategy. The 2024 Lancet Commission on dementia prevention, intervention, and care estimated that about 45% of dementia cases might be ...
Jul 16, 2026-- Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a nex ...
Four weeks of a 10-minute evening cosmetic routine with self-massage improved self-reported sleep quality, state anxiety, ...
Cancer therapy has dramatically changed over the past many decades, not only in efficacy but also complexity, with targeted ...
Alkaline phosphatase (ALP) is a membrane-bound glycoprotein, expressed in different tissues and playing several physiologic ...
Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the ...
Credit: Merck. Supported by the phase 3 CORALreef program, Merck’s once-daily oral macrocyclic peptide offers a non-injectable PCSK9-targeting pathway to significantly clear LDL-C in adults. Lipfendra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results